How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,062 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs

for damages arising from its use. Design by North Creative, Geneva. WHO/HTM/TB/2016.02 WHO Library Cataloguing-in-Publication Data Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs: consolidated guidelines. 1.HIV Infections. 2.Tuberculosis. 3.Drug Users. 4.Substance Abuse, Intravenous – complications. 5.Delivery of Health Care, Integrated. 6.Guideline. I.World Health Organization. II.The End TB Strategy. ISBN 978 92 4 151022 6 (NLM (...) for people who inject drugs | Consolidated Guidelines II. Definition of key terms People who inject drugs (PWID) refers to people who inject psychotropic (or psychoactive) substances for non- medical purposes. These drugs include opioids, amphetamine-type stimulants, cocaine, hypnotics/sedatives and hallucinogens. Injection may be through intravenous, intramuscular or subcutaneous routes. The definition does not include people who self-inject medicines for medical purposes, or individuals who self-inject

2016 World Health Organisation HIV Guidelines

82. Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs

Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs www.ccsa.ca • www.cclt.ca CCENDU Bulletin, June 2016 Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies Page 1 CCENDU Bulletin Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs Summary ? Counterfeit pharmaceuticals are fake products manufactured illegally in clandestine labs. They are designed to look like legitimate pharmaceuticals. ? Sale (...) is not an opioid. However, due to its analgesic effects and because it has been mixed in drugs sold illicitly as opioids, we have included it in this bulletin. For more information, see Health Canada’s clarification of its position on W-18: healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58866a-eng.php. CCENDU Bulletin: Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies Page 2 Pag

2016 Canadian Centre on Substance Abuse

83. Drugs That May Cause or Exacerbate Heart Failure

Drugs That May Cause or Exacerbate Heart Failure Drugs That May Cause or Exacerbate Heart Failure | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share (...) on Jump to Free Access article Drugs That May Cause or Exacerbate Heart Failure A Scientific Statement From the American Heart Association , PharmD, MSPH, FAHA, Chair , PharmD , MD, MSc , MD , MD, MSCE , MB ChB, FAHA , PharmD , and PhD, ACNP-BC, FAHA MD, FAHA, Co-ChairOn behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular

Full Text available with Trip Pro

2016 American Heart Association

84. Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines

completion of intensive-phase therapy is culture-positive) ? Treatment failure ? Relapse ? Drug resistance ? Homelessness ? Current or prior substance abuse ? Use of intermittent dosing ? HIV infection ? Previous nonadherence to therapy ? Children and adolescents ? Mental, emotional or physical disability (ie, cognitive deficits such as dementia; neurological deficits; medically fragile patients; or patients with blindness or severe loss of vision) ? Resident at correctional or long-term care facility (...) Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines Clinical Infectious Diseases IDSA GUIDELINE Of?cial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Payam Nahid, 1 Susan E. Dorman, 2 Narges Alipanah, 1 Pennan M. Barry, 3 Jan L. Brozek, 4 Adithya Cattamanchi, 1 Lelia H. Chaisson, 1 Richard E. Chaisson, 2 Charles L

2016 American Thoracic Society

85. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article (...) Share on Jump to Free Access article Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , MD, MSc, FRCPC, FAHA, Chair , MD, FAHA, Vice-Chair , MD, MS, FAHA , MD , DO , MD , MD, MS, FAHA , MD, MBA, FAHA , PhD , MD, MS, FAHA , MD, MSc, FAHA , and MD, FAHA MD, MPH, FAHAon behalf of the American Heart Association Stroke Council and Council

Full Text available with Trip Pro

2015 American Heart Association

86. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke

Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Scientific Rationale (...) for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , MD, MSc, FRCPC, FAHA, Chair , MD, FAHA, Vice-Chair , MD, MS, FAHA , MD , DO , MD , MD, MS, FAHA , MD, MBA, FAHA , PhD , MD, MS, FAHA , MD, MSc, FAHA , and MD, FAHA MD, MPH, FAHAon behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention Bart M. Demaerschalk , Dawn O

2015 American Academy of Neurology

87. Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease

or disease Intervention/treatment Phase Parkinson Disease Drug: Infudopa i.v. Drug: Infudopa s.c. Drug: LCIG (Duodopa) Phase 1 Detailed Description: IPO-001 is a prospective, randomized, 3-period cross-over, open-label multicentre trial comparing intravenous and subcutaneous Infudopa with intestinal Duodopa. The patients will be identified and recruited at neurology clinics at university hospital clinical sites in Sweden, and travel from their living location to a clinical phase I site with full Good (...) participation in any other clinical study Known drug abuse of any kind, or other condition that may render the patient more likely to be non-compliant to the protocol, as judged by the investigator Patients who are considered to be violent or patients considered at suicidal risk by the investigator Clinically significant abnormal laboratory data at baseline or any abnormal laboratory value that could interfere with the study assessments Patients with serious symptomatic cerebral disease, cerebrovascular

2018 Clinical Trials

88. Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section

of ketamine the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision. Drug: Ketamine the analgesic affects of ketamine will be compared between the experimental and placebo group. Other Name: ketamine hydrochloride Placebo Comparator: placebo they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision. Drug: Placebo the analgesic requirement will be calculated in placebo group. Outcome Measures Go to Primary Outcome (...) Last Verified: September 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ketamine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central

2018 Clinical Trials

89. Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study. (PubMed)

patients who presented with acute stroke symptoms was performed in 7 large inner-city US academic centers (various search years between 2000 and 2017). We collected data on HIV, National Institutes of Health Stroke Scale score, ischemic stroke risk factors, opportunistic infections, intravenous drug abuse, neuroimaging findings, and modified Rankin Scale score at last follow-up.We identified 33 HIV-infected patients treated with intravenous tPA (mean age, 51 years; 24 men), 10 of whom were stroke (...) no fatalities. Stroke mimics were common, and thrombolysis seems safe in this group. We found no data to suggest an increased risk of intravenous tPA-related complications because of concomitant opportunistic infections or intravenous drug abuse.© 2017 American Heart Association, Inc.

2018 Stroke

90. The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

of pain at multiple timepoints after surgery, and we will collect the additionally data from patients' medical records. Condition or disease Intervention/treatment Phase Pain, Postoperative Opioid Use Drug: Intravenous Lidocaine Infusion Drug: Placebo Infusion Phase 4 Detailed Description: Lidocaine has analgesic and anti-inflammatory effects. It has been shown to reduce early postoperative pain and nausea. Additionally, lidocaine has been shown to have positive effects in the recovery of bowel (...) Lumbar Spine Surgery Actual Study Start Date : June 4, 2018 Estimated Primary Completion Date : June 4, 2020 Estimated Study Completion Date : June 9, 2020 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Intravenous Lidocaine Infusion Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min. Drug: Intravenous Lidocaine Infusion Patients will be randomly

2018 Clinical Trials

91. Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

injury. Prior radiation therapy of the head or neck (within 1 year of Visit 1). History of malignancy within 2 years prior to Visit 1, with the exception of basal cell carcinoma. Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to Visit 1. Evidence of current alcohol or drug abuse, or history (...) Estimated Primary Completion Date : July 2020 Estimated Study Completion Date : April 2021 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Neridronic acid Neridronic acid administered by 4 intravenous infusions within 10 Days Drug: Neridronic acid Neridronic acid administered by 4 intravenous infusions within 10 Days Placebo Comparator: Placebo Matching placebo administered by 4 intravenous

2018 Clinical Trials

92. Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

Hypercholesterolemia Dyslipidemias Drug: Atorvastatin injection Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 52 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously (...) of daily oral atorvastatin for >= 4 weeks (oral atorvastatin may be provided during a lead-in period for subjects not previously taking atorvastatin) Stable LDL-C confirmed in the previous 7 to 10 days prior to enrollment into the treatment phase. Exclusion Criteria: History of myopathy or rhabdomyolysis Liver disease including current biliary disorders Positive for HIV, Hepatitis B or Hepatitis C Virus Abuse of alcohol or non-prescribed drugs Unstable angina or arrhythmias or a cardiac event

2018 Clinical Trials

93. Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers

, vaginally and transdermally. We will recruit 10 healthy female volunteers. The volunteers will have melatonin administered over 5 days; intravenously, rectally, intravesically, vaginally and transdermally. The participants will be followed for 24-48 hours with blood samples and questions about adverse events. There will be a wash-out between each session of a minimum of 7 days. Condition or disease Intervention/treatment Phase Melatonin Pharmacokinetics Safety Drug: Melatonin 25 mg Phase 1 Study Design (...) to understand Danish, written or spoken. Current use of melatonin or other hypnotics/sedatives Current pregnancy (a positive urine-HCG; the subjects will be tested prior to each study session) Breast feeding Current alcohol or drug abuse (defined as over 5 units of alcohol per day, or any usage of illegal drugs) Mental illness (defined as being in medical treatment) Serious comorbidity (American Society of Anesthesiologists (ASA) physical status 3-4) Participation in other clinical trials less than 1 month

2018 Clinical Trials

94. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

Recruitment Status : Completed First Posted : April 17, 2018 Last Update Posted : September 17, 2018 Sponsor: Orpheris, Inc. Information provided by (Responsible Party): Orpheris, Inc. Study Details Study Description Go to Brief Summary: A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers. Condition or disease Intervention/treatment Phase Healthy Drug: OP-101 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (...) Date : July 20, 2018 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cohort 1 20 mg/kg OP-101 administered intravenously for over 1 hour. Drug: OP-101 Intravenous Injection of OP-101 in healthy volunteers. Experimental: Cohort 2 40 mg/kg OP-101 administered intravenously for over 1 hour. Drug: OP-101 Intravenous Injection of OP-101 in healthy volunteers. Experimental: Cohort 3 (optional) 80 mg/kg OP-101

2018 Clinical Trials

95. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

or stomach, and ulcerative colitis. History of treatment with other investigational drug within 4 weeks of planned start of trial treatment. History of major surgery within 4 weeks of planned start of trial treatment. Has received a live virus vaccine within 4 weeks of planned start of trial treatment. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Has a history of severe hypersensitivity reaction to study drug. Has a history (...) A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

96. Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion

). Drug: Lidocaine ): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure). Other Name: Active group Placebo Comparator: Group II A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion. Drug: Normal saline (...) Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Serum

2018 Clinical Trials

97. Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

investigational study product within 28 days prior to enrollment. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy (...) Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2018 Clinical Trials

98. An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia

or intravenous glucocorticoids at doses of 20 mg and higher of prednisone daily or an equivalent dose of other glucocorticoids. Patients known to have HIV-positive status or AIDS or known to have other disease that seriously affects the immune system such as active haematological or solid organ malignancy, or splenectomy. History of drug or alcohol abuse. Patients have received quinolones or fluoroquinolones within 14 days before enrollment. Previous enrolment in this study or participation in another study (...) solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes. Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules). Drug: Nemonoxacin Solution for infusion, 500 mg (250 ml) Drug: Nemonoxacin Capsules, 250 mg Drug: Placebo (100 ml) 0.9% NaCl (100 ml), solution for infusion Active Comparator: Tavanic® Tavanic®

2018 Clinical Trials

99. Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

(e.g. IFN-α2a, IFN-α2b, IFN-β) Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer, including, clinically significant forms of: Drug or alcohol abuse Severe asthma Uncontrolled hypertension Type I diabetes mellitus, or type II diabetes mellitus that is not controlled with oral agents and/or insulin (i.e.: subjects with a history of diabetes mellitus and HA1C of > 9 in the last 3 months (...) transplantation with an existing functional graft Active autoimmune diseases, including autoimmune hepatitis History of retinopathy or clinically significant ophthalmologic disease Opportunistic infections or other active infectious diseases Other conditions, such as active drug/alcohol abuse or dependence, that in the opinion of the Investigator would interfere with study compliance. Initiation of treatment during acute infection Contacts and Locations Go to Information from the National Library of Medicine

2018 Clinical Trials

100. Efficacy and Safety of Intravenous Neridronic Acid in CRPS

of malignancy within 2 years prior to Visit 1, with the exception of basal cell carcinoma. Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to Visit 1. Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within 2 years of Visit 1, based on participant history and physical (...) : April 2021 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Neridronic acid Neridronic acid administered by 4 intravenous infusions within 10 Days Drug: Neridronic acid Neridronic acid administered by 4 intravenous infusions within 10 Days Placebo Comparator: Placebo Matching placebo administered by 4 intravenous infusions within 10 Days Drug: Placebo Matching placebo administered by 4

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>